Your browser doesn't support javascript.
loading
Clinical Analysis of 25 Non-Transplanted Multiple Myeloma Patients Treated with Bortezomib Maintenance / 中国实验血液学杂志
Article in Chinese | WPRIM | ID: wpr-880043
Responsible library: WPRO
ABSTRACT
OBJECTIVE@#To investigate the efficacy, survival and adverse effects of non-transplanted multiple myeloma (MM) patients treated with bortezomib maintenance.@*METHODS@#A total of 25 newly diagnosed/relapsed non-transplanted MM patients treated in West District of Beijing Chaoyang Hospital from June 2004 to November 2015 were analyzed retrospectively. All patients received PD regimen (bortezomib and dexamethasone), including bortezomib at a dose of 1.3 mg/m@*RESULTS@#Till November 1, 2017, 5 patients achieved stringent complete response (sCR), 8 patients achieved complete response (CR), 7 patients achieved very good partial response (VGPR), 4 patients achieved partial reponse (PR), while 1 patient achieved stable disease (SD). After maintenance therapy, 21 patients maintained the efficacy above PR, of which 1 patient was improved from CR to sCR; 4 patients adjusted chemotherapy after disease progressed. Median maintenance therapy was 9 cycles (range from 6 to 31), and the median maintenance time was 27 months (range from 18 to 97). Median follow-up time was 73 months (range from 25 to 171). Median progress-free survival (PFS) time was 30 months (range from 9 to 105) and overall survival (OS) time was 57 months (range from 27 to 160). Till November 1, 2019, 3-year survival rate was 84% (21/25), and 5-year survival rate was 72% (13/18). The most common adverse events were transient leukopenia, thrombocytopenia and peripheral neuropathy, which the patients could tolerate after the prevention and treatment.@*CONCLUSION@#Bortezomib-based maintenance therapy for non-transplanted MM patients can be an option in consideration of its safety and efficacy.
Subject(s)
Full text: Available Index: WPRIM (Western Pacific) Main subject: Humans / Dexamethasone / Antineoplastic Combined Chemotherapy Protocols / Retrospective Studies / Treatment Outcome / Disease-Free Survival / Bortezomib / Multiple Myeloma Language: Chinese Journal: Journal of Experimental Hematology Year: 2021 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Humans / Dexamethasone / Antineoplastic Combined Chemotherapy Protocols / Retrospective Studies / Treatment Outcome / Disease-Free Survival / Bortezomib / Multiple Myeloma Language: Chinese Journal: Journal of Experimental Hematology Year: 2021 Type: Article